Objective:To investigate the clinical significance and the expressions of the lung resistance protein(LRP),glutathione-S-transferase π(GST-π),excision repair cross-completion group 1(ERCC1)protein and Survivin protein in non-small cell lung cancer(NSCLC). Methods:LRP,GST-π,ERCC1 and Survivin protein in 64 specimens from NSCLC patients were detected using Envision immunohistochemical method,and the relationship was analyzed between the different protein expressions and the pathological classification,histological type,lymph node metastasis,clinical stage and the efficacy of platinum-based chemotherapy of NSCLC. Results:The positive rates of LRP,GST-π,ERCC1 protein and Survivin protein were 60.9%,56.3%,60.9% and 54.7% respectively. High expression of LRP was associated with poorly differentiated type(85.0%). The positive rate of GST-π decreased with the degradation of differentiation degree of NSCLC. The significant high positive rate of ERCC1 protein was observed in squamous cell carcinoma(80.0%). The positive rate of Survivin protein was significantly high in adenocarcinoma cell carcinoma(81.5%). There were significant differences in those proteins expressions among different carcinoma types. There was a positive correlation between the expression of LRP and the expression of GST-π(R=0.262,P=0.036). High expressions of ERCC1 protein and LRP were two independent factors related to platinum resistance by multivariate regression analysis. In ERCC1 negative NSCLC,the LRP positive patients’ remission rate of platinum-based chemotherapy was lower than the LRP negative patients’(P < 0.05). Conclusion:The expression levels of these proteins varied in different types of NSCLC. There was coordinate expression of LRP and GST-π. The combined detection of ERCCI and LRP proteins could be used to predict the sensitivity to platinum-based chemotherapy.